🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to researchers.

An International Challenge

The sexually transmitted infection are escalating globally, with estimates suggesting in excess of 82 million new cases annually. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are deeply concerned about the surge in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program revealed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for combating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Scientists believe that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval marks a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Data and Global Access

According to data detailed in a prominent scientific publication, the new drug eradicated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines a dual-drug approach. The research enrolled over 900 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous developing nations.

Medical professionals directly involved have voiced hope. The availability of a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is viewed as essential to lessen the impact of the illness for patients and to stop the proliferation of extremely resistant gonorrhoea worldwide.